Clinical trial
flt3L in Treating Patients With Acute Myeloid Leukemia
NCT00006223 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00006223 |
|---|---|
| Title | flt3L in Treating Patients With Acute Myeloid Leukemia |
| Official title | A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH Cancer and Leukemia Group B SWOG Cancer Research Network |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | recombinant flt3 ligand |
| Start date | Jul 1, 2000 |
| Completion | Jan 1, 2007 |
| First posted | Sep 3, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: